Study: Inositol & Airway Test To Help Detect Lung Cancer Early On
A New Screening Test And Inositol Therapy Against Early-Stage Lung Cancer
A new study published in the Science Translational Medicine journal shows the potential of a simple, non-invasive test to detect pre-cancerous cells to catch lung cancer in early stages. The test involves examining cells in the upper airway for signs of an activated molecular pathway that leads to cancer.
The premise is that the damage caused by cigarette smoke is not limited to the lung but rather forms a "field of injury" throughout the entire respiratory tract. Tissue from this extended injured area can be used to glean clinically relevant information about smoking-induced damage and disease, according to researchers. The novelty of the idea is that collecting cells from airways is less invasive than probing the lung issue.
What is more, the test can also be made therapeutic when combined with inositol therapy. There are studies investigating the ability of myo-inositol to shut down cancerous pathways in pre-cancerous cells. The advantage of myo-inositol is the relative lack of side effects. Unlike other chemicals with a similar mechanism of action, myo-inositol is well tolerated and has the potential to be taken orally for long periods of time. That means patients with sings of pre-cancerous cells in their airways can be treated with inositol early on to reverse the disease.
According to the American Cancer Society, lung cancer is still the deadliest cancer in the United States and most of the world.
Lung cancer killed nearly 160,000 Americans and about 20,500 Canadians in 2009.